pargyline has been researched along with Hepatocellular Carcinoma in 2 studies
Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Use of the tyrosine kinase inhibitor sorafenib in patients with advanced hepatocellular carcinoma (HCC) is often hindered by the development of resistance, which has been recently shown to be associated with the emergence of a cancer stem cell (CSC) subpopulation." | 7.85 | Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma. ( Chen, C; Chu, X; Geng, J; Han, D; Huang, M; Lei, Z; Wang, C; Wang, L; Wang, T; Wang, Y; Xie, T, 2017) |
| "Use of the tyrosine kinase inhibitor sorafenib in patients with advanced hepatocellular carcinoma (HCC) is often hindered by the development of resistance, which has been recently shown to be associated with the emergence of a cancer stem cell (CSC) subpopulation." | 3.85 | Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma. ( Chen, C; Chu, X; Geng, J; Han, D; Huang, M; Lei, Z; Wang, C; Wang, L; Wang, T; Wang, Y; Xie, T, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, M | 1 |
| Chen, C | 1 |
| Geng, J | 1 |
| Han, D | 1 |
| Wang, T | 1 |
| Xie, T | 1 |
| Wang, L | 1 |
| Wang, Y | 1 |
| Wang, C | 1 |
| Lei, Z | 1 |
| Chu, X | 1 |
| Doody, KM | 1 |
| Murry, BA | 1 |
| Mason, JI | 1 |
2 other studies available for pargyline and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Carcinoma | 2017 |
The use of rat Leydig tumor (R2C) and human hepatoma (HEPG2) cells to evaluate potential inhibitors of rat and human steroid aromatase.
Topics: Androstenedione; Animals; Antineoplastic Agents; Aromatase Inhibitors; Carcinoma, Hepatocellular; Ce | 1990 |